explore -WSS

explore

author：focus 2025-09-30 17:45:37 - browse：97

Adam's take main illustration — Molly Ferguson/STAT

Cytokinetics was founded 26 years ago but has not yet developed a drug successfully to approval. That makes Tuesday’s Food and Drug Administration decision on its treatment for heart failure a big deal — except nearly everyone, even investors who own Cytokinetics — hopes the agency rules against it.

Hoping the FDA rejects the Cytokinetics drug, called omecamtiv mecarbil, is a relatively uncommon, up-is-down, down-is-up situation, but it makes sense in this case because the business and science of the drug are not aligned.

Consider: Cytokinetics shares rose in December when an outside group of experts convened by the FDA to examine omecamtiv’s benefits and risks recommended against the medicine’s approval. On Tuesday, the FDA is most likely to heed that advice and turn down the company’s marketing application.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： A disappointing year of Humira biosimilars

entertainment

Wikipedia

WSS

Guardant Health colon cancer test endorsed by FDA advisory panel

New research sheds light on how often breast cancer is overdiagnosed

Why did Pfizer dish out millions for a Super Bowl ad?

Hospitals need to get ahead of regulations on climate change

Medical mystery: When a cough is not just a cough

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Wikipedia

explore

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medical students need to learn the potent medicine of empathy

Duchenne breakthrough therapy leaves behind pioneering families

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Hospitals need to get ahead of regulations on climate change

DIEP, the 'gold standard' of breast reconstruction, is under threat

Medical students need to learn the potent medicine of empathy

In age of alternative facts, a scholarly course on calling out crap

BioAge raises $170M for combination therapy with Zepbound

Wikipedia

Beyond aggravation: Constipation is an American epidemic

A disappointing year of Humira biosimilars

Industry veterans launch new biotech VC with $310M

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

For Medicare Advantage, Democrats want stronger protections around AI

Biden report: The neurospychology of memory and aging

focus

entertainment

Wikipedia

focus